The 35th CINP World Congress of Neuropsychopharmacology

セッション情報

[CINP2024] Poster Session

CINP2024 » Poster Session

Depression 2 - Preclinical (1)

2024年5月24日(金) 17:30 〜 18:30 CINP Poster Session Hall (Lobby Gallery)

*Leonard Lerer1, Katherine Spear1, Jeet Varia1, Cecily Keim1, Alex Buko2, Karin Blakolmer1, Bernard Lerer3 (1. Back of the Yards Algae Sciences - Parow Entheobiosciences, Chicago, IL, United States, 2. Human Metabolome Technologies, Boston, MA, United States, 3. Hadassah BrainLabs - Center for Psychedelic Research, Hadassah Medical Center, Hebrew University, Jerusalem, Israel)

*Naoto KAJITANI1,2,3, Mami OKADA-TSUCHIOKA3, Asuka INOUE4, Kanako MIYANO5,6, Takeshi MASUDA7, Shuken BOKU1, Kazuya IWAMOTO8, Sumio OHTSUKI7, Yasuhito UEZONO5, Junken AOKI9, Minoru TAKEBAYASHI1,3 (1. Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, 2. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, 3. Division of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization Kure Medical Center, 4. Laboratory of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 5. Department of Pain Control Research, The Jikei University School of Medicine, 6. Division of Cancer Pathophysiology, National Cancer Center Research Institute, 7. Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, 8. Department of Molecular Brain Science, Graduate School of Medical Sciences, Kumamoto University, 9. Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo)

*Yaxin Sun1, Yun-ai Su1, Qi Wang1,2, Jiaya Zheng1,2, Chenchen Zhang1,2, Ting Wang1, Xiao Liu1, Yunu Ma1, Xuexin Li1, Xianqiang Zhang1, Xiaomeng Xie1, Xiaodong Wang3, Jitao Li1, Tianmei Si1,2 (1. Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China, 2. Institute of Mental Health, Wenzhou Medical University, 325035 Wenzhou, China, 3. Department of Neurobiology, Key Laboratory of Medical Neurobiology of Ministry ofHealth of China, Zhejiang Province Key Laboratory of Neurobiology, Hangzhou, China)

*Junko Horie1, Tomoya Kinjo2, Masanobu Ito2, Toshihito Suzuki3 (1. Department of Psychiatry & Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan, 2. Department of Psychiatry, Faculty of Medicine, Juntendo University, Tokyo, Japan, 3. Department of Psychiatry, Juntendo Koshigaya Hospital, Saitama, Japan)

*Wataru Ukai1, Kenta Deriha1,4, Emi Nishimura1, Eri Hashimoto1, Misa Yamada5, Hanako Hashiguchi1, Shoma Hirose1,4, Marina Mochizuki1,6, Yukihiko Momoki1, Kengo Furuse1,6, Takao Ishii1,2, Kanna Nagaishi3, Marco A. Riva7, Chiaki Kawanishi1 (1. Dept. of Neuropsychiatry, Sapporo Medical Univ., Sapporo, Japan, 2. Dept. of Occupational Therapy, Sapporo Medical Univ., Sapporo, Japan, 3. Dept. of Anatomy II, Sapporo Medical Univ., Sapporo Japan, 4. Dept. of Psychiatry, Sunagawa City Hospital, Sunagawa, Japan, 5. Dept. of Neuropsychopharmacology, NIMH, NCNP, Tokyo, Japan, 6. Dept. of Psychiatry, Obihirokosei Hospital, Obihiro, Japan, 7. Dept. of Pharmacological & Biomolecular Science, Univ. of Milan, Milan, Italy)

*Martin Kuchar1, Klara Gotwaldova1, Jan Borovicka2, Radek Jurok3, Petra Cihlarova1, Katerina Hajkova1 (1. Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry nad Technology Prague, 2. Institute of Geology of the Czech Academy of Sciences, 3. Department of Organic Chemistry, University of Chemistry nad Technology Prague)

*Rei Yokoyama1, Yukio Ago2, Hisato Igarashi1, Momoko Higuchi1, Masato Tanuma1, Yuto Shimazaki1, Kaoru Seiriki1, Misuzu Hayashida1, Shun Yamaguchi3,4, Hirokazu Tanaka5, Takanobu Nakazawa6, Kenji Hashimoto7, Atsushi Kasai1,8, Hitoshi Hashimoto1,9,10,11,12 (1. Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, 2. Department of Cellular and Molecular Pharmacology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, 3. Department of Morphological Neuroscience, Graduate School of Medicine, Gifu University, Gifu, Japan, 4. Center for One Medicine Innovative Translational Research, Institute for Advanced Study, Gifu University, Gifu, Japan, 5. Faculty of Information Technology, Tokyo City University, Tokyo, Japan, 6. Department of Bioscience, Tokyo University of Agriculture, Tokyo, Japan, 7. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, 8. Systems Brain Science Project, Drug Innovation Center, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan, 9. Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan, 10. Division of Bioscience, Institute for Datability Science, Osaka University, Osaka, Japan, 11. Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan, 12. Department of Molecular Pharmaceutical Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan)

*Puji Rizki Suryani1, Eka Febri Zulissetiana2, Bintang Arroyantri Prananjaya1, Syarifah Aini1, Diyaz Syauki Ikhsan1 (1. Department of Psychiatry, Medical Faculty, Universitas Sriwijaya, Palembang, Indonesia, 2. Department of Physiology, Medical Faculty, Universitas Sriwijaya, Palembang, Indonesia)

×

認証

抄録パスワード認証
抄録の閲覧にはパスワードが必要です。パスワードを入力して認証してください。

×

要旨・抄録、PDFの閲覧には参加者用アカウントでのログインが必要です。参加者ログイン後に閲覧・ダウンロードできます。
» 参加者用ログイン